A carregar...
Imatinib Mesylate in Patients with WHO B3 Thymomas and Thymic Carcinomas
Thymic malignancies are rare tumors of the mediastinum. c-KIT is highly expressed in thymic carcinomas (TC) but infrequently in thymomas. Anecdotal experience suggests activity of imatinib mesylate in TC. Patients with unresectable World Health Organization B3 thymomas or TC, performance status 0 to...
Na minha lista:
| Publicado no: | J Thorac Oncol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7372705/ https://ncbi.nlm.nih.gov/pubmed/20197733 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e3181b6be57 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|